Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Personalized Medicine and Epigenomics
1.2 Key Market Segments
1.2.1 Personalized Medicine and Epigenomics Segment by Type
1.2.2 Personalized Medicine and Epigenomics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Personalized Medicine and Epigenomics Market Overview
2.1 Global Market Overview
2.1.1 Global Personalized Medicine and Epigenomics Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Personalized Medicine and Epigenomics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Personalized Medicine and Epigenomics Market Competitive Landscape
3.1 Global Personalized Medicine and Epigenomics Sales by Manufacturers (2019-2024)
3.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Manufacturers (2019-2024)
3.3 Personalized Medicine and Epigenomics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Personalized Medicine and Epigenomics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Personalized Medicine and Epigenomics Sales Sites, Area Served, Product Type
3.6 Personalized Medicine and Epigenomics Market Competitive Situation and Trends
3.6.1 Personalized Medicine and Epigenomics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Personalized Medicine and Epigenomics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Personalized Medicine and Epigenomics Industry Chain Analysis
4.1 Personalized Medicine and Epigenomics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Personalized Medicine and Epigenomics Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Personalized Medicine and Epigenomics Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Personalized Medicine and Epigenomics Sales Market Share by Type (2019-2024)
6.3 Global Personalized Medicine and Epigenomics Market Size Market Share by Type (2019-2024)
6.4 Global Personalized Medicine and Epigenomics Price by Type (2019-2024)
7 Personalized Medicine and Epigenomics Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Personalized Medicine and Epigenomics Market Sales by Application (2019-2024)
7.3 Global Personalized Medicine and Epigenomics Market Size (M USD) by Application (2019-2024)
7.4 Global Personalized Medicine and Epigenomics Sales Growth Rate by Application (2019-2024)
8 Personalized Medicine and Epigenomics Market Segmentation by Region
8.1 Global Personalized Medicine and Epigenomics Sales by Region
8.1.1 Global Personalized Medicine and Epigenomics Sales by Region
8.1.2 Global Personalized Medicine and Epigenomics Sales Market Share by Region
8.2 North America
8.2.1 North America Personalized Medicine and Epigenomics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Personalized Medicine and Epigenomics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Personalized Medicine and Epigenomics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Personalized Medicine and Epigenomics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Personalized Medicine and Epigenomics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Abbott Laboratories
9.1.1 Abbott Laboratories Personalized Medicine and Epigenomics Basic Information
9.1.2 Abbott Laboratories Personalized Medicine and Epigenomics Product Overview
9.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Product Market Performance
9.1.4 Abbott Laboratories Business Overview
9.1.5 Abbott Laboratories Personalized Medicine and Epigenomics SWOT Analysis
9.1.6 Abbott Laboratories Recent Developments
9.2 Affymetrix
9.2.1 Affymetrix Personalized Medicine and Epigenomics Basic Information
9.2.2 Affymetrix Personalized Medicine and Epigenomics Product Overview
9.2.3 Affymetrix Personalized Medicine and Epigenomics Product Market Performance
9.2.4 Affymetrix Business Overview
9.2.5 Affymetrix Personalized Medicine and Epigenomics SWOT Analysis
9.2.6 Affymetrix Recent Developments
9.3 Agilent Technologies
9.3.1 Agilent Technologies Personalized Medicine and Epigenomics Basic Information
9.3.2 Agilent Technologies Personalized Medicine and Epigenomics Product Overview
9.3.3 Agilent Technologies Personalized Medicine and Epigenomics Product Market Performance
9.3.4 Agilent Technologies Personalized Medicine and Epigenomics SWOT Analysis
9.3.5 Agilent Technologies Business Overview
9.3.6 Agilent Technologies Recent Developments
9.4 Astellas Pharmaceuticals
9.4.1 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Basic Information
9.4.2 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Product Overview
9.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Product Market Performance
9.4.4 Astellas Pharmaceuticals Business Overview
9.4.5 Astellas Pharmaceuticals Recent Developments
9.5 BAYER AG
9.5.1 BAYER AG Personalized Medicine and Epigenomics Basic Information
9.5.2 BAYER AG Personalized Medicine and Epigenomics Product Overview
9.5.3 BAYER AG Personalized Medicine and Epigenomics Product Market Performance
9.5.4 BAYER AG Business Overview
9.5.5 BAYER AG Recent Developments
9.6 Bio Vision
9.6.1 Bio Vision Personalized Medicine and Epigenomics Basic Information
9.6.2 Bio Vision Personalized Medicine and Epigenomics Product Overview
9.6.3 Bio Vision Personalized Medicine and Epigenomics Product Market Performance
9.6.4 Bio Vision Business Overview
9.6.5 Bio Vision Recent Developments
9.7 Celgene Corp.
9.7.1 Celgene Corp. Personalized Medicine and Epigenomics Basic Information
9.7.2 Celgene Corp. Personalized Medicine and Epigenomics Product Overview
9.7.3 Celgene Corp. Personalized Medicine and Epigenomics Product Market Performance
9.7.4 Celgene Corp. Business Overview
9.7.5 Celgene Corp. Recent Developments
9.8 Emd Millipore
9.8.1 Emd Millipore Personalized Medicine and Epigenomics Basic Information
9.8.2 Emd Millipore Personalized Medicine and Epigenomics Product Overview
9.8.3 Emd Millipore Personalized Medicine and Epigenomics Product Market Performance
9.8.4 Emd Millipore Business Overview
9.8.5 Emd Millipore Recent Developments
9.9 Epigenomics AG
9.9.1 Epigenomics AG Personalized Medicine and Epigenomics Basic Information
9.9.2 Epigenomics AG Personalized Medicine and Epigenomics Product Overview
9.9.3 Epigenomics AG Personalized Medicine and Epigenomics Product Market Performance
9.9.4 Epigenomics AG Business Overview
9.9.5 Epigenomics AG Recent Developments
9.10 Epigentex
9.10.1 Epigentex Personalized Medicine and Epigenomics Basic Information
9.10.2 Epigentex Personalized Medicine and Epigenomics Product Overview
9.10.3 Epigentex Personalized Medicine and Epigenomics Product Market Performance
9.10.4 Epigentex Business Overview
9.10.5 Epigentex Recent Developments
9.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
9.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Basic Information
9.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Product Overview
9.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Product Market Performance
9.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
9.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Developments
9.12 Gilead Sciences
9.12.1 Gilead Sciences Personalized Medicine and Epigenomics Basic Information
9.12.2 Gilead Sciences Personalized Medicine and Epigenomics Product Overview
9.12.3 Gilead Sciences Personalized Medicine and Epigenomics Product Market Performance
9.12.4 Gilead Sciences Business Overview
9.12.5 Gilead Sciences Recent Developments
9.13 Glaxosmithkline
9.13.1 Glaxosmithkline Personalized Medicine and Epigenomics Basic Information
9.13.2 Glaxosmithkline Personalized Medicine and Epigenomics Product Overview
9.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Product Market Performance
9.13.4 Glaxosmithkline Business Overview
9.13.5 Glaxosmithkline Recent Developments
9.14 Illumina Inc.
9.14.1 Illumina Inc. Personalized Medicine and Epigenomics Basic Information
9.14.2 Illumina Inc. Personalized Medicine and Epigenomics Product Overview
9.14.3 Illumina Inc. Personalized Medicine and Epigenomics Product Market Performance
9.14.4 Illumina Inc. Business Overview
9.14.5 Illumina Inc. Recent Developments
9.15 Johnson and Johnson
9.15.1 Johnson and Johnson Personalized Medicine and Epigenomics Basic Information
9.15.2 Johnson and Johnson Personalized Medicine and Epigenomics Product Overview
9.15.3 Johnson and Johnson Personalized Medicine and Epigenomics Product Market Performance
9.15.4 Johnson and Johnson Business Overview
9.15.5 Johnson and Johnson Recent Developments
9.16 Karus Therapeutics Limited
9.16.1 Karus Therapeutics Limited Personalized Medicine and Epigenomics Basic Information
9.16.2 Karus Therapeutics Limited Personalized Medicine and Epigenomics Product Overview
9.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Product Market Performance
9.16.4 Karus Therapeutics Limited Business Overview
9.16.5 Karus Therapeutics Limited Recent Developments
9.17 Laboratory Corp. Of America Holdings
9.17.1 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Basic Information
9.17.2 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Product Overview
9.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Product Market Performance
9.17.4 Laboratory Corp. Of America Holdings Business Overview
9.17.5 Laboratory Corp. Of America Holdings Recent Developments
9.18 LES Laboratoires Servier
9.18.1 LES Laboratoires Servier Personalized Medicine and Epigenomics Basic Information
9.18.2 LES Laboratoires Servier Personalized Medicine and Epigenomics Product Overview
9.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Product Market Performance
9.18.4 LES Laboratoires Servier Business Overview
9.18.5 LES Laboratoires Servier Recent Developments
9.19 Merck
9.19.1 Merck Personalized Medicine and Epigenomics Basic Information
9.19.2 Merck Personalized Medicine and Epigenomics Product Overview
9.19.3 Merck Personalized Medicine and Epigenomics Product Market Performance
9.19.4 Merck Business Overview
9.19.5 Merck Recent Developments
9.20 Naturewise Biotech and Medicals Corp.
9.20.1 Naturewise Biotech and Medicals Corp. Personalized Medicine and Epigenomics Basic Information
9.20.2 Naturewise Biotech and Medicals Corp. Personalized Medicine and Epigenomics Product Overview
9.20.3 Naturewise Biotech and Medicals Corp. Personalized Medicine and Epigenomics Product Market Performance
9.20.4 Naturewise Biotech and Medicals Corp. Business Overview
9.20.5 Naturewise Biotech and Medicals Corp. Recent Developments
9.21 Novartis Pharma AG
9.21.1 Novartis Pharma AG Personalized Medicine and Epigenomics Basic Information
9.21.2 Novartis Pharma AG Personalized Medicine and Epigenomics Product Overview
9.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Product Market Performance
9.21.4 Novartis Pharma AG Business Overview
9.21.5 Novartis Pharma AG Recent Developments
9.22 Oncolys Biopharma Inc.
9.22.1 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Basic Information
9.22.2 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Product Overview
9.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Product Market Performance
9.22.4 Oncolys Biopharma Inc. Business Overview
9.22.5 Oncolys Biopharma Inc. Recent Developments
9.23 Orchid Chemicals and Pharmaceuticals Limited
9.23.1 Orchid Chemicals and Pharmaceuticals Limited Personalized Medicine and Epigenomics Basic Information
9.23.2 Orchid Chemicals and Pharmaceuticals Limited Personalized Medicine and Epigenomics Product Overview
9.23.3 Orchid Chemicals and Pharmaceuticals Limited Personalized Medicine and Epigenomics Product Market Performance
9.23.4 Orchid Chemicals and Pharmaceuticals Limited Business Overview
9.23.5 Orchid Chemicals and Pharmaceuticals Limited Recent Developments
9.24 Progen Pharmaceuticals Limited
9.24.1 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Basic Information
9.24.2 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Product Overview
9.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Product Market Performance
9.24.4 Progen Pharmaceuticals Limited Business Overview
9.24.5 Progen Pharmaceuticals Limited Recent Developments
9.25 Quest Diagnostics
9.25.1 Quest Diagnostics Personalized Medicine and Epigenomics Basic Information
9.25.2 Quest Diagnostics Personalized Medicine and Epigenomics Product Overview
9.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Product Market Performance
9.25.4 Quest Diagnostics Business Overview
9.25.5 Quest Diagnostics Recent Developments
9.26 Roche Holding AG
9.26.1 Roche Holding AG Personalized Medicine and Epigenomics Basic Information
9.26.2 Roche Holding AG Personalized Medicine and Epigenomics Product Overview
9.26.3 Roche Holding AG Personalized Medicine and Epigenomics Product Market Performance
9.26.4 Roche Holding AG Business Overview
9.26.5 Roche Holding AG Recent Developments
9.27 Rubicon Genomics
9.27.1 Rubicon Genomics Personalized Medicine and Epigenomics Basic Information
9.27.2 Rubicon Genomics Personalized Medicine and Epigenomics Product Overview
9.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Product Market Performance
9.27.4 Rubicon Genomics Business Overview
9.27.5 Rubicon Genomics Recent Developments
9.28 Takeda Pharmaceutical Company Limited
9.28.1 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Basic Information
9.28.2 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Product Overview
9.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Product Market Performance
9.28.4 Takeda Pharmaceutical Company Limited Business Overview
9.28.5 Takeda Pharmaceutical Company Limited Recent Developments
10 Personalized Medicine and Epigenomics Market Forecast by Region
10.1 Global Personalized Medicine and Epigenomics Market Size Forecast
10.2 Global Personalized Medicine and Epigenomics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Personalized Medicine and Epigenomics Market Size Forecast by Country
10.2.3 Asia Pacific Personalized Medicine and Epigenomics Market Size Forecast by Region
10.2.4 South America Personalized Medicine and Epigenomics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Personalized Medicine and Epigenomics by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Personalized Medicine and Epigenomics Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Personalized Medicine and Epigenomics by Type (2025-2030)
11.1.2 Global Personalized Medicine and Epigenomics Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Personalized Medicine and Epigenomics by Type (2025-2030)
11.2 Global Personalized Medicine and Epigenomics Market Forecast by Application (2025-2030)
11.2.1 Global Personalized Medicine and Epigenomics Sales (K Units) Forecast by Application
11.2.2 Global Personalized Medicine and Epigenomics Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
